NCT07643467
Fluorescent Probe for Assessment of Renal Elimination
Not Yet Recruiting
PHASE4Ages 18–65InterventionalDiagnosticAaron CookInvestigator-initiated
~200 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:RelmapirazinIohexolMedibeacon tGFR monitorUrine creatinine clearance collection
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Transdermal Glomerular Filtration Rate (tGFR) Monitoring Accuracy
Measured over 8 Hours
Conditions
Where it's being run
1 sites across 1 statesKentucky1
Study leadership
- Aaron M Cook, PharmD · PRINCIPAL_INVESTIGATOR · University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science
- Juan-Carlos Aycinena, MD · STUDY_DIRECTOR · University of Kentucky College of Medicine, Department of Nephrology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
18-65 years old
critically ill or acutely ill hospitalized patients admitted to the intensive care unit
Stable/normal renal function
Exclusion
Prisoners
Pregnant women
Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr \> 1.5x baseline)
What this trial measures
- Transdermal Glomerular Filtration Rate (tGFR) Monitoring Accuracy8 Hours
Accuracy of transdermal glomerular filtration rate (GFR) monitoring compared with measured urine creatinine clearance.